Evidence map›Paper›PMID 28202705›Full record

ArticleNeurology2017

Moderators and predictors of response to behavior therapy for tics in Tourette syndrome.

Denis G Sukhodolsky, Douglas W Woods, John Piacentini, Sabine Wilhelm, Alan L Peterson, Lily Katsovich, James Dziura, John T Walkup, Lawrence Scahill

3 registry-linked trialsOpen access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 43 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 5 pooled it
14.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00218777 phase2 / phase3completednot on this map

Behavior Therapy for Children With Chronic Tic Disorders

TypeinterventionalSponsorTourette Association of AmericaRan2004 to 2007Enrolled120ConditionsTourette Syndrome, Tic DisordersArmsComprehensive Behavioral Intervention for Tics
NCT00231985 phase2completednot on this map

Behavior Therapy and Psychosocial Treatment for Tourette Syndrome and Chronic Tic Disorder

TypeinterventionalSponsorMassachusetts General HospitalRan2005 to 2010Enrolled122ConditionsTourette Syndrome, Tic DisordersArmsHabit reversal therapy, Supportive therapy
NCT03705988 naunknown statusnot on this mapstarted 2018, after this paper: background citation

A Double-blind, Randomized, Sham-controlled Study of Cranial Electrotherapy Stimulation as an Add-on Treatment for Tic Disorders in Children and Adolescents(SCATT)

TypeinterventionalSponsorXijing HospitalRan2018 to 2019Enrolled100ConditionsTic Disorder, ChildhoodArmsCranial Electrotherapy Stimulation(CES), sham Cranial Electrotherapy Stimulation( sham CES)
3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 5 syntheses or guidelines pooled it, 119 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Guideline
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Review
  17. Meta-anlaysis of Internet-based Behavior Therapy for Tic Disorder.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2025
    Article
  18. Evidence-Based Behavior Therapy for Tourette Syndrome.The Psychiatric clinics of North America · 2025
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Denis G SukhodolskyFrom Yale University School of Medicine (D.G.S., L.K., J.D.), New Haven, CT; Marquette University (D.W.W.), Milwaukee, WI; University of California at Los Angeles Geffen School of Medicine (J.P.); Massachusetts General Hospital/Harvard Medical School (S.W.), Boston; University of Texas Health Science Center at San Antonio (A.L.P.); Weill Cornell Medical College (J.T.W.), New York, NY; and Marcus Autism Center (L.S.), Emory University School of Medicine, Atlanta, GA. denis.sukhodolsky@yale.edu.
Douglas W WoodsFrom Yale University School of Medicine (D.G.S., L.K., J.D.), New Haven, CT; Marquette University (D.W.W.), Milwaukee, WI; University of California at Los Angeles Geffen School of Medicine (J.P.); Massachusetts General Hospital/Harvard Medical School (S.W.), Boston; University of Texas Health Science Center at San Antonio (A.L.P.); Weill Cornell Medical College (J.T.W.), New York, NY; and Marcus Autism Center (L.S.), Emory University School of Medicine, Atlanta, GA.
John PiacentiniFrom Yale University School of Medicine (D.G.S., L.K., J.D.), New Haven, CT; Marquette University (D.W.W.), Milwaukee, WI; University of California at Los Angeles Geffen School of Medicine (J.P.); Massachusetts General Hospital/Harvard Medical School (S.W.), Boston; University of Texas Health Science Center at San Antonio (A.L.P.); Weill Cornell Medical College (J.T.W.), New York, NY; and Marcus Autism Center (L.S.), Emory University School of Medicine, Atlanta, GA.
Sabine WilhelmFrom Yale University School of Medicine (D.G.S., L.K., J.D.), New Haven, CT; Marquette University (D.W.W.), Milwaukee, WI; University of California at Los Angeles Geffen School of Medicine (J.P.); Massachusetts General Hospital/Harvard Medical School (S.W.), Boston; University of Texas Health Science Center at San Antonio (A.L.P.); Weill Cornell Medical College (J.T.W.), New York, NY; and Marcus Autism Center (L.S.), Emory University School of Medicine, Atlanta, GA.
Alan L PetersonFrom Yale University School of Medicine (D.G.S., L.K., J.D.), New Haven, CT; Marquette University (D.W.W.), Milwaukee, WI; University of California at Los Angeles Geffen School of Medicine (J.P.); Massachusetts General Hospital/Harvard Medical School (S.W.), Boston; University of Texas Health Science Center at San Antonio (A.L.P.); Weill Cornell Medical College (J.T.W.), New York, NY; and Marcus Autism Center (L.S.), Emory University School of Medicine, Atlanta, GA.
Lily KatsovichFrom Yale University School of Medicine (D.G.S., L.K., J.D.), New Haven, CT; Marquette University (D.W.W.), Milwaukee, WI; University of California at Los Angeles Geffen School of Medicine (J.P.); Massachusetts General Hospital/Harvard Medical School (S.W.), Boston; University of Texas Health Science Center at San Antonio (A.L.P.); Weill Cornell Medical College (J.T.W.), New York, NY; and Marcus Autism Center (L.S.), Emory University School of Medicine, Atlanta, GA.
James DziuraFrom Yale University School of Medicine (D.G.S., L.K., J.D.), New Haven, CT; Marquette University (D.W.W.), Milwaukee, WI; University of California at Los Angeles Geffen School of Medicine (J.P.); Massachusetts General Hospital/Harvard Medical School (S.W.), Boston; University of Texas Health Science Center at San Antonio (A.L.P.); Weill Cornell Medical College (J.T.W.), New York, NY; and Marcus Autism Center (L.S.), Emory University School of Medicine, Atlanta, GA.
John T WalkupFrom Yale University School of Medicine (D.G.S., L.K., J.D.), New Haven, CT; Marquette University (D.W.W.), Milwaukee, WI; University of California at Los Angeles Geffen School of Medicine (J.P.); Massachusetts General Hospital/Harvard Medical School (S.W.), Boston; University of Texas Health Science Center at San Antonio (A.L.P.); Weill Cornell Medical College (J.T.W.), New York, NY; and Marcus Autism Center (L.S.), Emory University School of Medicine, Atlanta, GA.
Lawrence ScahillFrom Yale University School of Medicine (D.G.S., L.K., J.D.), New Haven, CT; Marquette University (D.W.W.), Milwaukee, WI; University of California at Los Angeles Geffen School of Medicine (J.P.); Massachusetts General Hospital/Harvard Medical School (S.W.), Boston; University of Texas Health Science Center at San Antonio (A.L.P.); Weill Cornell Medical College (J.T.W.), New York, NY; and Marcus Autism Center (L.S.), Emory University School of Medicine, Atlanta, GA.
Cornell University · USHarvard University · USMassachusetts General Hospital · USMarquette University · USThe University of Texas Health Science Center at San Antonio · USUniversity of California, Los Angeles · US

Funding

Behavior Therapy for Adults with Tourette SyndromeR01MH069874 · NIMH · YALE UNIVERSITY · PI SCAHILL, LAWRENCE D. · 2005 to 2009
$1.2M
Behavior Therapy for Adults with Tourette SyndromeR01MH069877 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI WILHELM, SABINE · 2005 to 2009
$918k
Neurobiology of Behavior Therapy for Children with Tourette SyndromeK01MH079130 · NIMH · YALE UNIVERSITY · PI SUKHODOLSKY, DENIS G · 2008 to 2012
$833k
NIMH NIH HHS K01 MH079130NIMH NIH HHS R01 MH069874NIMH NIH HHS R01 MH069877
6 · The paper itself

Abstract

objectiveTo examine moderators and predictors of response to behavior therapy for tics in children and adults with Tourette syndrome and chronic tic disorders.

methodsData from 2 10-week, multisite studies (1 in children and 1 in adults; total n = 248) comparing comprehensive behavioral intervention for tics (CBIT) to psychoeducation and supportive therapy (PST) were combined for moderator analyses. Participants (177 male, 71 female) had a mean age of 21.5 ± 13.9 years (range 9-69). Demographic and clinical characteristics, baseline tic-suppressing medication, and co-occurring psychiatric disorders were tested as potential moderators for CBIT vs PST or predictors of outcome regardless of treatment assignment. Main outcomes measures were the Yale Global Tic Severity Scale Total Tic score and the Clinical Global Impression-Improvement score assessed by masked evaluators.

resultsThe presence of tic medication significantly moderated response to CBIT vs PST (

conclusionsPresence of co-occurring attention-deficit/hyperactivity disorder, obsessive-compulsive disorder, or anxiety disorders did not moderate response to CBIT. Although participants on tic medication showed improvement after CBIT, the difference between CBIT and PST was greater for participants who were not on tic-suppressing medication. CLINICALTRIALSGOV IDENTIFIERS: The child and adult CBIT studies are listed on clinical trials.gov (NCT00218777 and NCT00231985, respectively). CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that CBIT is effective in reducing tic severity across subgroups of patients with chronic tic disorders, although the difference between treatments was smaller for participants on tic-suppressing medications, suggesting reduced efficacy in this subgroup.

Indexed as

Treatment OutcomeAdolescentAdultAgedAttention Deficit Disorder with HyperactivityBehavior TherapyChildFemaleHumansMaleMiddle AgedOutcome Assessment, Health CarePredictive Value of TestsTicsTourette SyndromeYoung Adult

Identifiers

PMID28202705
PMCPMC5384839
OpenAlexW2588198995

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.